joozy
2021-09-23

Simufilam Merits Accelerated Approval

The FDA gave accelerated approval to aducanumab on the basis of a surrogate, although, in a large trial aducanumab did not slow cognitive decline and exhibited damaging SAE’S (brain bleeds etc), and furthermore, notwithstanding a negative vote of 29/30 members of ADCOM.

Why ? Apparently, the FDA were desperate to give an impression of progress because, notwithstanding many past efforts over many years, alzheimers remains incurable.

In contrast, Simufilam actually does slow cognitive decline -in one year, a highly significant 8 % swing over historic norms (by meta analysis) ---- without any damaging side effects. Additionally, it reduces several AZ biomarkers at a high level of significance.

As Simufilam does no harm, ethically Cassava should apply for accelerated approval now enabling patients access while the 18 month ph 3 trial is ongoing, providing a riskless opportunity of saving many hundreds of thousands of lives otherwise lost in the interim$Cassava Sciences Inc(SAVA)$

buy it

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • breAkdaWn
    2021-09-24
    breAkdaWn

    FDA gave accelerated approval?? means FDA can be manipulated? alzheimers: instead of finding a cure. fine a prevention!! find a way to detect and prevent before AD happens

Leave a comment
1